MedTrace Logo

Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses

NCT03327831 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-06-27

Study results available
· View outcomes & findings →

Summary

Photodynamic therapy is an effective treatment for actinic keratoses. In the United States topical aminolevulinic acid (ALA) is approved as a photosensitizing agent for this treatment, and it has traditionally been activated with the use of an in-office artificial light source. This clinical trial seeks to measure the safety and efficacy of using natural sunlight to activate the ALA.

Conditions

  • Actinic Keratosis

Interventions

DRUG

Aminolevulinic Acid

Topical application followed by activation by ambient sunlight

Sponsors & Collaborators

  • University of California, Irvine

    lead OTHER

Principal Investigators

  • Christopher B Zachary, MBBS. FRC[ · University of California, Irvine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-02-28
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03327831 on ClinicalTrials.gov